NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

AZAHAR Study To Describe Anifrolumab in a Real-World Setting

CompletedN/A

Sponsor: AstraZeneca

Conditions: Systemic Lupus Erythematosus (SLE)

Countries: Spain

AZAHAR is an observational retrospective and longitudinal study with adults patients with SLE who initiated treatment with anifrolumab from June 1, 2023 to May 31, 2024. The overall objective is to describe the characteristics and clinical outcomes of patients with SLE that initiated anifrolumab during its first year of commercialization in Spain.

Eligibility overview

Sex: ALL

Age: 18 Years to 130 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Fulfilled the 2019 EULAR/ACR criteria for SLE at the date of anifrolumab initiation.
* Aged 18 years or older at the date of anifrolumab initiation.
* Have initiated anifrolumab between June 1st, 2023, and May 31st, 2024
* Have at least 12 months of medical history prior to anifrolumab initiation.

Exclusion Criteria:

* Current or previous exposure to anifrolumab as part of a clinical trial or Early Access Program (EAP).

Locations (13)

Barcelona, Spain
Granada, Spain
Jaén, Spain
L'Hospitalet de Llobregat, Spain
León, Spain
Madrid, Spain
Málaga, Spain
Mérida, Spain
Móstoles, Spain
Murcia, Spain
Seville, Spain
Toledo, Spain
Valladolid, Spain